Led · Equity · Nov 2022

Ateria Health is a U.K.-based health and wellness biotech focused on gut microbiome products and research. The company owns ERME™ intellectual property and has commercialised JUVIA™ Digestive Balance Formula for the treatment of irritable bowel syndrome (IBS). Ateria develops and distributes supplements and has research interests in Australia. As part of its commercial strategy, the company intends reciprocal distribution arrangements to expand JUVIA™ into Australian and North American markets. The business is positioned to collaborate on joint R&D and leverage partner distribution channels to reach B2C online platforms, pharmacies, and retail. No operating financial metrics were disclosed in the article.

Led · Equity · Oct 2022

Immuron develops and commercialises oral immunotherapeutic products targeting gut-mediated diseases, including its Travelan® travel-diarrhea product. The company is pursuing an organic growth and M&A strategy built on expanding market verticals, customer base, distribution and product offerings. Immuron has committed cash reserves to a strategic equity investment in Ateria Health to gain exposure to the IBS market and complementary products. Management intends to leverage reciprocal distribution, joint R&D and sales & marketing to expand Travelan® and incorporate Ateria’s JUVIA™ in new markets. The company funded the upfront investment from existing cash reserves and views the deal as the first milestone in its stated growth strategy.